JP2020529410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529410A5 JP2020529410A5 JP2020505208A JP2020505208A JP2020529410A5 JP 2020529410 A5 JP2020529410 A5 JP 2020529410A5 JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020505208 A JP2020505208 A JP 2020505208A JP 2020529410 A5 JP2020529410 A5 JP 2020529410A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023075458A JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2025092507A JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539421P | 2017-07-31 | 2017-07-31 | |
| US62/539,421 | 2017-07-31 | ||
| PCT/US2018/044610 WO2019028027A1 (en) | 2017-07-31 | 2018-07-31 | PROTEINS BINDING TO NKG2D, CD16 AND FLT3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075458A Division JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529410A JP2020529410A (ja) | 2020-10-08 |
| JP2020529410A5 true JP2020529410A5 (enExample) | 2021-09-24 |
Family
ID=65233032
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505208A Pending JP2020529410A (ja) | 2017-07-31 | 2018-07-31 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2023075458A Pending JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2025092507A Pending JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023075458A Pending JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2025092507A Pending JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200165344A1 (enExample) |
| EP (1) | EP3661554A4 (enExample) |
| JP (3) | JP2020529410A (enExample) |
| KR (2) | KR20250051800A (enExample) |
| CN (1) | CN111132698A (enExample) |
| AU (2) | AU2018309712A1 (enExample) |
| BR (1) | BR112020001972A2 (enExample) |
| CA (1) | CA3070986A1 (enExample) |
| CO (1) | CO2020001981A2 (enExample) |
| EA (1) | EA202090387A1 (enExample) |
| IL (1) | IL272374A (enExample) |
| MA (1) | MA49769A (enExample) |
| MX (1) | MX2020001257A (enExample) |
| SG (1) | SG11202000632QA (enExample) |
| WO (1) | WO2019028027A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| MA52206A (fr) | 2018-03-27 | 2021-02-17 | Xyphos Biosciences Inc | Domaines a1-a2 modifiés de ligands nkg2d non naturels se liant à des récepteurs nkg2d non naturels |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EP3902836B1 (en) | 2018-12-18 | 2026-03-25 | Boehringer Ingelheim IO Canada Inc. | Flt3 agonist antibodies and uses thereof |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| BR112022016550A2 (pt) * | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| JP2024524378A (ja) * | 2021-06-29 | 2024-07-05 | 山▲東▼先声生物制▲薬▼有限公司 | Ｃｄ１６抗体及びその応用 |
| WO2026052582A1 (en) | 2024-09-04 | 2026-03-12 | Red Ridge Bio Ag | Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009077483A1 (en) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| ES2573642T3 (es) * | 2009-12-23 | 2016-06-09 | Synimmune Gmbh | Anticuerpos anti-FLT3 y métodos de usar los mismos |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| EP4310191A3 (en) * | 2012-06-14 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified fc region |
| EP4050026A1 (en) * | 2014-04-01 | 2022-08-31 | Adimab, LLC | Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
-
2018
- 2018-07-31 BR BR112020001972-0A patent/BR112020001972A2/pt not_active Application Discontinuation
- 2018-07-31 US US16/635,079 patent/US20200165344A1/en not_active Abandoned
- 2018-07-31 CN CN201880062880.1A patent/CN111132698A/zh active Pending
- 2018-07-31 JP JP2020505208A patent/JP2020529410A/ja active Pending
- 2018-07-31 EA EA202090387A patent/EA202090387A1/ru unknown
- 2018-07-31 MX MX2020001257A patent/MX2020001257A/es unknown
- 2018-07-31 KR KR1020257011280A patent/KR20250051800A/ko active Pending
- 2018-07-31 MA MA049769A patent/MA49769A/fr unknown
- 2018-07-31 AU AU2018309712A patent/AU2018309712A1/en not_active Abandoned
- 2018-07-31 KR KR1020207005238A patent/KR20200033302A/ko not_active Ceased
- 2018-07-31 CA CA3070986A patent/CA3070986A1/en active Pending
- 2018-07-31 SG SG11202000632QA patent/SG11202000632QA/en unknown
- 2018-07-31 EP EP18840650.8A patent/EP3661554A4/en active Pending
- 2018-07-31 WO PCT/US2018/044610 patent/WO2019028027A1/en not_active Ceased
-
2020
- 2020-01-30 IL IL272374A patent/IL272374A/en unknown
- 2020-02-25 CO CONC2020/0001981A patent/CO2020001981A2/es unknown
-
2023
- 2023-05-01 JP JP2023075458A patent/JP2023106433A/ja active Pending
-
2025
- 2025-06-03 JP JP2025092507A patent/JP2025131681A/ja active Pending
- 2025-06-19 AU AU2025204591A patent/AU2025204591A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023106433A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| Krah et al. | Engineering bispecific antibodies with defined chain pairing | |
| JP2023052214A5 (enExample) | ||
| JP2020507328A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021534096A5 (enExample) | ||
| JP2022551969A5 (enExample) | ||
| JP2023526774A5 (enExample) | ||
| JP2022545196A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| JP2019023184A5 (enExample) | ||
| JP2020510646A5 (enExample) | ||
| JP2023538945A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2021530236A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| CA3232364A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| JP2020531525A5 (enExample) | ||
| JP2022537931A5 (enExample) | ||
| JP2022505445A5 (enExample) | ||
| CN106397598B (zh) | 多价多特异性抗体及免疫杂合蛋白的表达和制备方法 | |
| JP2023532129A5 (enExample) |